{"id":"NCT00449176","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","officialTitle":"A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2007-03-20","resultsPosted":"2010-06-24","lastUpdate":"2012-04-30"},"enrollment":981,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"tapentadol (CG5503) ER","otherNames":[]},{"type":"DRUG","name":"oxycodone CR","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"ACTIVE_COMPARATOR"},{"label":"003","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain of the lower back, in comparison with placebo and Oxycodone Controlled Release (CR).","primaryOutcome":{"measure":"Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Tapentadol ER","deltaMin":-2.9,"sd":2.66},{"arm":"Oxycodone CR","deltaMin":-2.9,"sd":2.52},{"arm":"Placebo","deltaMin":-2.1,"sd":2.33}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24985410","24916058","24353047","23709304","23340531"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=68&filename=CR013399_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Nausea","Headache","Constipation","Dizziness","Somnolence"]}}